anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The intervention is a 6-month prospective interventional pilot study targeted to each domain of frailty. Subjects will be screened into the study by testing each domain; only those who meet criteria for frailty will be included in the study. The clinical intervention, which all subjects will receive, will begin immediately upon enrollment and completion of baseline measurements. Upon enrollment the 3 most recent previous outpatient serum creatinine measurements (up to 1 year) will be used to determine baseline slope of estimated glomerular filtration rate (eGFR). The main objectives of the pilot study will be to gain knowledge in the successful implementation and completion of an intervention targeted toward frailty. Ultimately information ascertained from this pilot will serve as a springboard for planning of a randomized trial aimed at addressing all the domains of frailty, which is key given that previous studies have only implemented interventions aimed at a single domain or in pairs, but no studies have evaluated the extent to which frailty can be reversed through a cohesive intervention addressing all domains together. The intervention outlined in this proposal is comprehensive and focused while maintaining feasibility.
1314634 Coriolin B and diketocoriolin B ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI 19 April 1971 [13 Feb 1970] 21673/71 Heading C2A The novel compound coriolin B having the formula is produced by aerobically cultivating the Basidiomycete, Coriolus consors (ATCC 20305) in aqueous nutrient medium and isolating the coriolin B thus produced. The compound is mainly in the mycelium of the culture and is isolated by separating off the liquid portion and extracting the mycelium with an appropriate solvent, e.g. methanol, butanol, acetone or butyl acetate, concentrating the solution and precipitating the coriolin B with a non-solvent, e.g. n-hexane, water or carbon tetrachloride. Coriolin B forms white crystals melting at 215‹ to 216‹C. The novel antibiotic diketocoriolin B of formula is obtained by oxidizing coriolin B with chromic anhydride in acetic acid. It forms white crystals melting at 147‹ to 148‹ C. and has anti-tumour and antibacterial properties.
Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
FIELD: pharmaceutics, phytotherapy. SUBSTANCE: the present innovation deals with treating patients with ulcerous disease with Helicobacter pylori (HP). The preparation is suggested as herbal species including common wormwood grass, buckbean leaves, common centaury grass, dandelion roots, perforated St. John's wort grass, common licorice root, rhizome with sweet flag roots, flax seed, pansy grass, yarrow grass, European elder flowers, burnet rhizomes, corn stigmas, sand immortelle flowers, eucalyptus leaves, tansy flowers, wild rosemary grass, creeping thyme grass, mountain cranberry leaves taken at certain ratio. Application of the present preparation enables to improve regenerative processes of mucous membrane and healing ulcerous "niche". EFFECT: shortened terms of therapy. 4 ex
The recommended starting dosage of JORNAY PM in patients 6 years and older is 20 mg once daily orally in the evening. Do not take JORNAY PM in the morning. The dose may be titrated weekly in increments of 20 mg. A daily dosage above 100 mg has not been studied and is not recommended. 

Initiate dosing at 8:00 p.m. Adjust the timing of administration between 6:30 p.m. and 9:30 p.m. to optimize the tolerability and efficacy the next morning and throughout the day. In clinical trials of patients aged 6 to 12 years, the most common dosing time (>70% of patients) was 8:00 p.m., with an allowed range between 6:30 p.m. and 9:30 p.m. Following determination of the optimal administration time, advise patients to maintain a consistent dosing time. 

Advise patients to take JORNAY PM consistently, either with food or without food. 

Patients who miss their dose of JORNAY PM at the regularly scheduled time should take it as soon as they remember that same evening. If a patient remembers the missed dose the following morning, they should skip the missed dose and wait until their next scheduled evening administration.
PURPOSE: To obtain the subject absorbefacient, comprising (methoxy-methylethyl)- methylcyclohexanol, excellent in percutaneous absorbefacient effects of a pharmacodynamic effective ingredient and having high safety and usability. CONSTITUTION: This percutaneous absorbefacient comprises 2-(2-methoxy-1- methylethyl)-5-methylcyclohexanol. The compound is preferably used in an amount of 0.5-10wt.% based on the total amount of the pharmaceutical preparation with a pharmacodynamic effective ingredient such as a (non)steroidal antiinflammatory agent, an antiallergic agent, an agent for the central nerve or an analgesic agent. The content of the pharmacodynamic effective ingredient is preferably 0.5-10wt.% based on the pharmaceutical preparation. Furthermore, e.g. a cataplasma, an ointment, a get or a cream is cited as the dosage form of the percutaneous absorbable type pharmaceutical preparation.
Complete response (CR) in advanced breast cancer is an important predictor of improved survival. The largest experience reported with long-term follow-up in this regard is from M.D. Anderson Hospital, with a median survival of 33 months and 5-year survival of 19% among patients who achieved a CR with doxorubicin-based chemotherapy.19 We believe that our institutional experience to date indicates that CR rates in excess of 20% can be achieved in second-line chemotherapy from the combination of vinorelbine and a taxane, provided that G-CSF is given. For the reasons outlined, we believe that dose density is likely to be important for both classes of agents, but dose intensity may be most important for vinorelbine. Both paclitaxel and docetaxel can be given on a weekly schedule with some success, but it appears that myelosuppression is a more frequent dose-limiting toxicity on this schedule for docetaxel. For the current trial, we therefore propose to study weekly paclitaxel in combination with dose-intensive vinorelbine, utilizing continuous G-CSF support as in our prior studies. We believe that starting doses of 60 mg/m2 for paclitaxel and 20 mg/m2 for vinorelbine will be well tolerated, but our experience to date, treating 3 patients off study at these doses without G-CSF support, indicates that some will require G-CSF even at this dose level: we observed grade 4 neutropenia in 2 of the 3. Our intention in this trial is to determine the optimal dose of these two agents when continuous growth factor support is provided. We will be starting at a ratio of 0.8 for vinorelbine and 0.75 for paclitaxel (assuming 80 mg/m2/week as a "full" dose for the later agent).

It is now widely appreciated that patients with metastatic breast cancer whose tumors over express HER-2-neu demonstrate benefit from the addition of trastuzumab (Herceptin) to a chemotherapy program with paclitaxel as a single agent.20 Such patients will be allowed to receive trastuzumab in the standard dose and schedule (4 mg/kg loading dose, then 2 mg/kg/week) given IV, in addition to paclitaxel and vinorelbine. Since trastuzumab does not produce myelosuppression or neuropathy (the anticipated dose-limiting toxicities for vinorelbine and paclitaxel, respectively), and neither of these agents combined separately with trastuzumab produces unusual or severe new side effects, this should not affect the dose escalation scheme for the chemotherapeutic agents.
PCT No. PCT/IB95/00455 Sec. 371 Date Dec. 5, 1996 Sec. 102(e) Date Dec. 5, 1996 PCT Filed Jun. 8, 1995 PCT Pub. No. WO95/33765 PCT Pub. Date Dec. 14, 1995Novel backbone cyclized peptide analogs are formed by means of bridging groups attached via the alpha nitrogens of amino acid derivatives to provide novel non-peptidic linkages. Novel building units disclosed are N alpha ( omega -functionalized)amino acids constructed to include a spacer and a terminal functional group. One or more of these N alpha ( omega -functionalized) amino acids are incorporated into a peptide sequence, preferably during solid phase peptide synthesis. The reactive terminal functional groups are protected by specific protecting groups that can be selectively removed to effect either backbone-to-backbone or backbone-to-side chain cyclizations. The invention is exemplified by backbone cyclized bradykinin antagonists having biological activity. Further embodiments of the invention are somatostatin analogs having one or two ring structures involving backbone cyclization.
Some vertebrates evolved to have a remarkable capacity for anatomical and physiological plasticity in response to environmental challenges. One example of such plasticity can be found in the ambush-hunting snakes of the genus Python, which exhibit reversible cardiac growth with feeding. The predation strategy employed by pythons is associated with months-long fasts that are arrested by ingestion of large prey. Consequently, digestion compels a dramatic increase in metabolic rate and hypertrophy of multiple organs, including the heart. In this Review, we summarize the post-prandial cardiac adaptations in pythons at the whole-heart, cellular and molecular scales. We highlight circulating factors and cellular signaling pathways that are altered during digestion to affect cardiac form and function and propose possible mechanisms that may drive the post-digestion regression of cardiac mass. Adaptive physiological cardiac hypertrophy has also been observed in other vertebrates, including in fish acclimated to cold water, birds flying at high altitudes and exercising mammals. To reveal potential evolutionarily conserved features, we summarize the molecular signatures of reversible cardiac remodeling identified in these species and compare them with those of pythons. Finally, we offer a perspective on the potential of biomimetics targeting the natural biology of pythons as therapeutics for human heart disease.
Identifying specific markers of adipose stem and progenitor cells (ASPCs) in vivo is crucial for understanding the biology of white adipose tissues (WAT). PDGFRα-positive perivascular stromal cells represent the best candidates for ASPCs. This cell lineage differentiates into myofibroblasts that contribute to the impairment of WAT function. However, ASPC marker protein(s) that are functionally crucial for maintaining WAT homeostasis are unknown. We previously identified Meflin as a marker of mesenchymal stem cells (MSCs) in bone marrow and tissue-resident perivascular fibroblasts in various tissues. We also demonstrated that Meflin maintains the undifferentiated status of MSCs/fibroblasts. Here, we show that Meflin is expressed in WAT ASPCs. A lineage-tracing experiment showed that Meflin+ ASPCs proliferate in the WAT of obese mice induced by a high-fat diet (HFD), while some of them differentiate into myofibroblasts or mature adipocytes. Meflin knockout mice fed an HFD exhibited a significant fibrotic response as well as increases in adipocyte cell size and the number of crown-like structures in WAT, accompanied by impaired glucose tolerance. These data suggested that Meflin expressed by ASPCs may have a role in reducing disease progression associated with WAT dysfunction.
PURPOSE:A stable nicorandil tablet obtained by blending nicorandil with a specific saturated higher fatty acid or saturated higher alcohol. CONSTITUTION:A tablet obtained by blending a composition of nicorandil [N-(2- hydroxyethyl)nicotinamide nitrate] with >=0.5wt% one or a mixture of two or more of saturated higher fatty acids, e.g. palmitic acid, stearic acid, etc., or saturated higher alcohols, e.g. cetyl alcohol, stearyl alcohol, etc., which are solid at ordinary temperature. The above-mentioned composition is prepared by blending nicorandil crystals with a pharmaceutical carrier, e.g. excipient, disintegrating agent, lubricant, colorant, binder, etc. The remedy has coronary vasodilator and coronary arterial contraction inhibitory action and is a remedy for various disease types of angina pectoris hardly affecting cardiac blood circulation kinetics and cardiac function. EFFECT:A step of coating the nicorandil crystals is not required.
The invention involves a pharmaceutical composition for treating coronary artery stenosis of coronary heart disease, its preparation method and application. The pharmaceutical composition for treating coronary artery stenosis of coronary heart disease is composed of L- methyl folate salt, coenzyme Q10, methyl vitamin B12, arginine and magnesium oxide as raw materials and supplemented with appropriate dose ratio. The pharmaceutical composition for the treatment of coronary artery stenosis of coronary heart disease is finally prepared. Various raw material components play a synergistic role in improving the function of vascular endothelial cells, eliminating myocardial cell inflammatory factors, and improving myocardial activity. It can effectively metabolize the formed atherosclerosis, dissolve thrombus by thrombolysis, and directly act on the lesion, so as to achieve the purpose of reversing coronary artery stenosis of coronary heart disease. The invention overcomes the defect that the existing technology cannot obtain the imaging improvement effect, and can well achieve lesion reversal and good prognosis.
To date, patients over the age of 60 yrs represent 25% of the population and are at increased risk of surgical repair. Reduction of postoperative morbidity and mortality are now two main concerns for medical research. Dependence on caregivers and cognitive impairments are two major risks in the elderly and even more in frail patients after surgery under general anesthesia. In this context continuous monitoring of the depth of anesthesia through bispectral index may reduce its occurrence with better control of too deep sedation periods (vasopressors...). Previous studies by the investigators' team suggest a better duration in the expected interval of Bispectral Index with automated control of administration of intravenous anesthetics guided by Bispectral Index. This method remains to be tested in this high-risk population. As a consequence, a randomization into two groups will be carried on elderly patients (\> 70 yrs): manual administration of anesthetics guided by Bispectral Index (manual group) or automated administration (automated group). Complete preoperative assessments will determine the FRAIL status (with a decrease in the physiological reserve) and abilities of the patient according to the self-sufficient scale. At six months a follow-up will determine the geriatric status of the patient to explore the rate of impairment and to examine predictive factors in the preoperative assessment. Finally, the influence of the method of administration will be reported. Four hundred and thirty patients will be included in this multicenter study with 215 patients per group and stratification of the presence of a cancer and of the abdominal repair. The follow-up in this study allows the patient or his/her relatives to keep in touch with a physician and to prescribe some therapy early if frailty or any other cognitive impairment appears.
PURPOSE: A cosmetic composition containing dilauroyl glutamic acid lysine and N-acetylglucosamine is provided to improve anti-wrinkle and skin moisturization. CONSTITUTION: A cosmetic composition for skin protection contains dilauroyl glutamic acid lysine non-toxic salt, and N-acetylglucosamine as active ingredients. The composition is used for skin moisturization or anti-wrinkle. The dilauroyl glutamic acid lysine non-toxic salt is sodium dilyuroyl glutamic acid lysine. The composition contains 30 weight parts of N-acetyl glucosamine based on 100 weight parts of dilauroyl glutamic acid lysine. The composition further contains cosmetically acceptable additive. The additive is solubilizer, stabilizing agent, emulsifying agent, vitamin, pigment, perfume, or mixture thereof.
Based on its mechanism of action, MONJUVI may cause fetal B-cell depletion when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with MONJUVI and for at least 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

MONJUVI is initially administered in combination with lenalidomide. The combination of MONJUVI with lenalidomide is contraindicated in pregnant women because lenalidomide can cause birth defects and death of the unborn child. Refer to the lenalidomide prescribing information on use during pregnancy.
Currently kidney transplantation is the only viable option for patients with kidney failure to regain quality of life and health. The number of organs available for transplantation is insufficient with a widening gap between supply and demand. Nowadays, centers accept older and higher risk donor organs with co-morbidity, often leading to non-function, complications and with half of the patients back on dialysis within 15 years. Furthermore, many donor kidneys have to be discarded as too damaged and beyond repair. Increasing the quality and therefore transplantability of these high-risk donor organs could significantly increase the donor kidney pool.

Using prolonged normothermic perfusion of marginal donor organs, the investigators aim to kick start regeneration in the kidney before transplantation, improving function and survival long-term. Furthermore, the choice to accept or decline a donor kidney organ is currently based on subjective criteria and causes great uncertainty amongst clinicians. There is a dire need for tools to aid in decision making and reduce this uncertainty. Biomarkers predictive of graft regeneration are lacking. Samples from perfused kidneys and donor recipients will be collected and analysed to allow the formulation of a kidney fitness index.
PURPOSE:To provide a novel antibiotic substance SS7313B having specific elemental analysis value, EI-mass spectrum, melting point, specific rotation, UV- absorption spectrum, molecular formula, etc. CONSTITUTION:The novel antibiotic substance of the present invention produced by the microbial strain (FERM-P No.7367) is named as SS7313B. The culture of the strain capable of producing the antibiotic substance SS7313B can be carried out by the conventional cultivation method for actinomycetes. Usually, it is preferable to culture in a liquid medium under shaking or in a deep tank with aeration, under aerobic condition at 25-30 deg.C. The antibiotic substance SS7313B produced by the cultivation exists usually in the cell and in the culture liquid. Accordingly, the SS7313B is separated and purified by separating the cell from the liquid by filtration, etc., and separating the SS7313B from both fractions by conventional method. The SS7313B has a molecular formula of C7H8N2O4, and a plane structure of the formula.
The invention belongs to the technical field of skin care products, and in particular relates to toning lotion with functions of moisturizing and resisting senility, and a preparation method of the toning lotion. The invention provides the toning lotion with the functions of moisturizing and resisting senility so as to solve the problem that the common skin care product can not be used by sensitive skin due to irritation. The toning lotion is prepared from the following raw materials in parts by weight: 0.5-2 parts of hydrolyzed collagen, 0.1-1 part of sodium hyaluronate, 0.1-1.5 parts of ginkgo biloba extract, 0.1-1.5 parts of tea extract, 0.1-1.5 parts of chamomilla recutita flower extract, 0.1-1.5 parts of scutellaria baicalensis root extract, 0.1-1.5 parts of licorice root extract and 90-99 parts of deionized water. The invention also provides the preparation method of the toning lotion with the functions of moisturizing and resisting senility; the method comprises the following steps: a. weighing the raw materials; b. preparing a sodium hyaluronate solution; c. preparing the toning lotion with the functions of moisturizing and resisting senility. The toning lotion has better moisturizing and senility resisting effects, is mild and non-irritating, and is suitable for daily maintenance of normal skin and sensitive skin. The preparation method is simple and easy to operate, and is suitable for industrial application.
PURPOSE: To obtain a medicine containing 2-(4-methylaminobutoxy) diphenylmethane as an active ingredient reduced in side effects, and useful for the therapy of infant autism. CONSTITUTION: The autism therapeutic agent contains a compound of the formula, and its hydrate, or their salts as active ingredients. The compound of the formula can be administered as such, but is preferably mixed with conventional additives and subsequently prepared into an oral, percutaneous or transmucosal administration form. The active ingredient is orally administered at a dose of 5-300mg (as the amount of the active ingredient), especially 150mg, per a day for an adult, and the oral administration dose for a child is converted from the oral administration for the adult. The application target for the therapeutic agent is the autism of children, e.g. 4-12 year old children.  The autism therapeutic agent is useful for the therapy of diffuse development disorders comprising a group of disorders characterized by qualitative disorders in the patterns of mutual social relations and communications and by the widths of circumscribed, stereotyped and repeated interests and actions, and is further useful for the reduction in the disease states.
For the active C5/C6 group (active control; same sensation different nerve), the electrodes will be placed over cervical nerves five and six, to mimic the sensation, but change the location. A current similar to active NITESGON will be applied.
Serial analysis of gene expression (SAGE) was used to identify transcripts encoding secreted or cell-surface proteins that were expressed in benign and malignant tumors of the colorectum. A total of 290,394 tags were analyzed from normal, adenomatous and cancerous colonic epithelium. Of the 21,343 different transcripts observed, 957 were found to be differentially expressed between normal and adenoma or between normal and cancer. Forty-nine transcripts were elevated ≥ 20-fold in adenomas, 40 transcripts were elevated ≥ 20-fold in cancers, and nine transcripts were elevated ≥ 20-fold in both. Product of six these nine transcripts (TGFBI, LYS, RDP, MIC-1, REGA, and DEHL) were predicted to be secreted or to reside on the cell surface and these were analyzed in more detail. The abnormal expression levels predicted by SAGE were confirmed by quantitative PCR analyses of each of these six genes. Moreover, the cell types responsible for the elevated expression were identified by in situ hybridization and by PCR analyses of epithelial cells immunoaffinity purified from primary tumors.
The present application provides a surgical computing system that can scan a sensing system located in an operating room. Upon detecting a sensing system in the operating room, the surgical computing system may establish a link with the sensing system. The surgical computing system may receive user role identification data from the sensing system using the established link. The surgical computing system may identify a user role of a user in the operating room based on the received user role identification data. The user role of the user may be or may include at least one of: a surgeon, nurse, patient, hospital staff, or healthcare professional. Based on the identified user role, the surgical computing system can generate and transmit surgical assistance information for the user in the operating room. The surgical assistance information may include information associated with a surgical procedure related to the identified user role.